{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T04:55:26Z","timestamp":1769316926548,"version":"3.49.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007647","name":"National Taiwan University College of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007647","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Emergency Medicine"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.ajem.2022.03.030","type":"journal-article","created":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T13:25:00Z","timestamp":1647609900000},"page":"395.e1-395.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Severe immune thrombocytopenia following COVID-19 vaccination (Moderna) and immune checkpoint inhibitor"],"prefix":"10.1016","volume":"56","author":[{"given":"Kah-Meng","family":"Chong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Yao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Chin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wan-Ching","family":"Lien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.ajem.2022.03.030_bb0005","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1056\/NEJMoa2104882","article-title":"Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination","volume":"384","author":"Schultz","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajem.2022.03.030_bb0010","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2021.2833","article-title":"Myocarditis following immunization with mRNA COVID-19 vaccines in members of the US military","author":"Montgomery","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"16","key":"10.1016\/j.ajem.2022.03.030_bb0015","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1182\/blood-2010-08-302984","article-title":"The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia","volume":"117","author":"Neunert","year":"2011","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.ajem.2022.03.030_bb0020","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/s41591-021-01419-1","article-title":"COVID-19 vaccination and immune thrombocytopenia","volume":"27","author":"Pishko","year":"2021","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.ajem.2022.03.030_bb0025","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.4161\/hv.23601","article-title":"Vaccine administration and the development of immune thrombocytopenic purpura in children","volume":"9","author":"Cecinati","year":"2013","journal-title":"Hum Vaccin Immunother"},{"issue":"5","key":"10.1016\/j.ajem.2022.03.030_bb0030","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/ajh.26132","article-title":"Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination","volume":"96","author":"Lee","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ajem.2022.03.030_bb0035","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2147\/JBM.S307047","article-title":"Severe, refractory immune thrombocytopenia occurring after SARS-CoV-2 vaccine","volume":"12","author":"Helms","year":"2021","journal-title":"J Blood Med"},{"issue":"3","key":"10.1016\/j.ajem.2022.03.030_bb0040","article-title":"Purpuric rash and thrombocytopenia after the mRNA-1273 (Moderna) COVID-19 vaccine","volume":"13","author":"Malayala","year":"2021","journal-title":"Cureus"},{"issue":"6","key":"10.1016\/j.ajem.2022.03.030_bb0045","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.annemergmed.2021.02.011","article-title":"Idiopathic thrombocytopenic Purpura and the Moderna Covid-19 vaccine","volume":"77","author":"Julian","year":"2021","journal-title":"Ann Emerg Med"},{"issue":"5","key":"10.1016\/j.ajem.2022.03.030_bb0050","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2021-242220","article-title":"Secondary immune thrombocytopenia supposedly attributable to COVID-19 vaccination","volume":"14","author":"Fueyo-Rodriguez","year":"2021","journal-title":"BMJ Case Rep"},{"issue":"8","key":"10.1016\/j.ajem.2022.03.030_bb0055","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000618","article-title":"Autoimmune hematologic disorders in two patients after mRNA COVID-19 vaccine","volume":"5","author":"Gaignard","year":"2021","journal-title":"Hemasphere"},{"issue":"5","key":"10.1016\/j.ajem.2022.03.030_bb0060","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.26106","article-title":"Immune thrombocytopenia in a 22-year-old post Covid-19 vaccine","volume":"96","author":"Tarawneh","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ajem.2022.03.030_bb0065","first-page":"341","article-title":"Immune thrombocytopenia following the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine","volume":"23","author":"Chezi Ganzel","year":"2021","journal-title":"IMAJ"},{"issue":"25","key":"10.1016\/j.ajem.2022.03.030_bb0070","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1016\/j.vaccine.2021.04.054","article-title":"Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the vaccine adverse event reporting system (VAERS)","volume":"39","author":"Welsh","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.ajem.2022.03.030_bb0075","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.530478","article-title":"Immune thrombocytopenia induced by immune checkpoint inhibitors in solid cancer: case report and literature review","volume":"10","author":"Liu","year":"2020","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.ajem.2022.03.030_bb0080","doi-asserted-by":"crossref","DOI":"10.1002\/ccr3.4227","article-title":"Drug-induced immune-mediated thrombocytopenia secondary to durvalumab use","volume":"9","author":"Dougherty","year":"2021","journal-title":"Clin Case Rep"},{"key":"10.1016\/j.ajem.2022.03.030_bb0085","series-title":"YERVOY (ipilimumab)","author":"Bristol-Myers Squibb Company","year":"2022"},{"key":"10.1016\/j.ajem.2022.03.030_bb0090","series-title":"OPDIVO (nivolumab)","author":"Bristol-Myers Squibb Company","year":"2022"},{"key":"10.1016\/j.ajem.2022.03.030_bb0095","series-title":"KEYTRUDA (pembrolizumab)","author":"Merck Sharp & Dohme Corp","year":"2022"},{"key":"10.1016\/j.ajem.2022.03.030_bb0100","series-title":"IMFINZI (durvalumab)","author":"AstraZeneca Pharmaceuticals LP","year":"2022"},{"issue":"4","key":"10.1016\/j.ajem.2022.03.030_bb0105","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/ijc.33822","article-title":"Risk factors for immune-related adverse events from anti-PD-1 or anti-PD-L1 treatment in an Asian cohort of nonsmall cell lung cancer patients","volume":"150","author":"Yiqing Huang","year":"2022","journal-title":"Int J Cancer"},{"issue":"26","key":"10.1016\/j.ajem.2022.03.030_bb0110","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.2217\/fon-2021-0288","article-title":"Indications for and contraindications of immune checkpoint inhibitors in cancer patients with coronavirus disease 2019 vaccination","volume":"17","author":"Luo","year":"2021","journal-title":"Future Oncol"},{"key":"10.1016\/j.ajem.2022.03.030_bb0115","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejca.2019.07.014","article-title":"Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?","volume":"122","author":"Michot","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ajem.2022.03.030_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.idcr.2021.e01344","article-title":"Immune thrombocytopenia relapse post covid-19 vaccine in young male patient","volume":"26","author":"Qasim","year":"2021","journal-title":"IDCases"}],"container-title":["The American Journal of Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735675722001887?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735675722001887?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:02:28Z","timestamp":1760025748000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735675722001887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":24,"alternative-id":["S0735675722001887"],"URL":"https:\/\/doi.org\/10.1016\/j.ajem.2022.03.030","relation":{},"ISSN":["0735-6757"],"issn-type":[{"value":"0735-6757","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Severe immune thrombocytopenia following COVID-19 vaccination (Moderna) and immune checkpoint inhibitor","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Emergency Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajem.2022.03.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}